Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2006-07-04
2006-07-04
Siew, Jeffrey (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C514S002600
Reexamination Certificate
active
07071294
ABSTRACT:
A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vivo or in vitro are provided.
REFERENCES:
patent: 0911397 (1999-04-01), None
patent: 1041146 (2000-04-01), None
patent: 1055684 (2000-11-01), None
patent: 97/46676 (1997-12-01), None
patent: 99/29715 (1999-06-01), None
patent: 99/33977 (1999-07-01), None
patent: WO 99/45954 (1999-09-01), None
patent: 99/54461 (1999-10-01), None
Evans et al Q.J.Med 1999;92:299-307.
Gura (Science, v278, 1997, pp. 1041-1042).
Nagase et al (DNA Res. Oct. 1998 ; 5(5):277-286).
Merriam-Webster Online “composition”.
Gene Number (KIAA): 0764, Acc. No. ABO18307.
Nakao et al., “HLA A2601-restricted CTLs Recognize a Peptide Antigen Expressed on Squamous Cell Carcinoma”; Cancer Research; vol. 55, pp. 4248-4252; (1995).
Kubo et al., “Definition of Specific Peptide Motifs for Four Major HLA-A Alleles”; J.of Immunology, vol. 152, pp. 3913-3924 (1994).
Kondo et al., “Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules”; J.of Immunology, vol. 155, pp. 4307-4312 (1995).
Sudo et al., “Differences in MHC Class I Self Peptide Repertoires among HLA-A2 Subtypes”; The J. of Immunology, vol. 155, pp. 4749-4756 (1995).
Rivoltini et al., “Induction of Tumor-Reactive CTL from peripheral Blood and Tumor-infiltrating Lymphocytes of Melanoma Patients by In Vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART-1”, The J. of Immunology, vol. 154, pp. 2257-2265 (1995).
Kharkevitch et al., “Characterization of Autologous Tumor-Specific T-Helper 2 Cells in Tumor-Infiltrating Lymphocytes from a patient with Metastatic Melanoma”, Int.J.Cancer, vol. 58, pp. 317-323 (1994).
Thomsen et al., “Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination”, The J. of Immunology, vol. 160, pp. 1717-1723 (1998).
Tsai et al., “Identification of Subdominant CTL Epitopes of the GP100 Melanoma-Associated Tumor Antigen by Primary in Vitro Immunization with Peptide-Pulsed Dendritic Cells”, The J. of Immunology, vol. 158, pp. 1796-1802 (1997).
Rosenberg et al., “ Treatment of Patients with Metastatic Melanoma with Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2”, J.Natl.Cancer Inst., vol. 86, pp. 1159-1166 (1994).
Altman et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes”, Science, vol. 274, pp. 94-96 (1996).
Rammensee et al., “MHC ligands and peptide motifs: first listing”; Immunogenetics, vol. 41, pp. 178-228 (1995).
Rammensee et al., Immunogenetics, vol. 41, pp. 178-228, (1995).
Nagase, T. et al., DNA Res. (Oct. 30, 1998) vol. 5, p.277-286.
Shichijo, S et al. J. Exp. Med. (Feb. 1998) vol. 187, No. 3, p.277-288.
Gomi Shinya
Itoh Kyogo
Green Peptide Co., Ltd.
Siew Jeffrey
Yaen C.
LandOfFree
Tumor antigen protein art-1 and tumor antigen peptide thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor antigen protein art-1 and tumor antigen peptide thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor antigen protein art-1 and tumor antigen peptide thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3526433